Skip to main content
Clinical Trials/DRKS00012624
DRKS00012624
Completed
Not Applicable

FDG-PET/CT in patients with pulmonary cancer: quantitative analyses for improved detection of lymph node metastases - Bro-Ly-Q-PET

niversitätsklinikum Magdeburg0 sites73 target enrollmentJuly 27, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C34
Sponsor
niversitätsklinikum Magdeburg
Enrollment
73
Status
Completed
Last Updated
last year

Overview

Brief Summary

Purpose: Pre-operative assessment of thoracic lymphonodal (LN) involvement in patients with lung cancer (LC) is crucial when choosing the treatment modality. Visual assessment of F-18-FDG-PET/CT (PET/CT) is well established, however, there is still a need for prospective quantitative data to differentiate benign from malignant lesions which would simplify staging and guide the further implementation of computer-aided diagnosis (CAD). Methods: In this prospective study, 37 patients with confirmed lung cancer (m/f = 24/13; age: 70 [52-83] years) were analyzed. All patients underwent PET/CT and quantitative data (standardized uptake values) were obtained. Histological results were available for 101 thoracic lymph nodes. Quantitative data were matched to determine cut-off values for delineation between benign vs. malignant lymph nodes. Furthermore, a scoring system derived from these cut-off values was established. Statistical analyses were performed through ROC analysis. Results: Quantitative analysis revealed the optimal cut-off values (p < 0.01) for the differentiation between benign and malignant thoracic lymph nodes in patients suffering from lung cancer. The respective areas under the curve (AUC) ranged from 0.86 to 0.94. The highest AUC for a ratio of lymph node to healthy lung tissue was 0.94. The resulting accuracy ranged from 78.2% to 89.1%. A dedicated scoring system led to an AUC of 0.93 with a negative predictive value of 95.4%. Conclusion: Quantitative analysis of F-18-FDG-PET/CT data provides reliable results for delineation between benign and malignant thoracic lymph nodes. Thus, quantitative parameters can improve diagnostic accuracy and reliability and can also facilitate the handling of the steadily increasing number of clinical examinations.

Registry
who.int
Start Date
July 27, 2017
End Date
January 30, 2018
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Magdeburg

Eligibility Criteria

Inclusion Criteria

  • FDG\-PET/CT for primary staging of pulmonary cancer, informed consent, age \> 18 years, sufficient histological information

Exclusion Criteria

  • non\-existence of informed consent, withdrawal of informed consent, missing histology, pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials